Table of Contents Jardiance (Empagliflozin) Product Category Diabetes & Heart Failure SGLT2 Inhibitor Generic Name or Biosimilar No Active Ingredient Empagliflozin Prescription Status Prescription-only Targeted Conditions Jardiance is approved to treat the following conditions: Type 2 Diabetes Mellitus (T2DM), to improve glycemic control Heart Failure with Reduced Ejection Fraction (HFrEF), to reduce the risk of cardiovascular death and hospitalization Chronic Kidney Disease (CKD), to slow progression and improve renal outcomes Off-Label Usage Some off-label uses being studied or prescribed include: Heart Failure with Preserved Ejection Fraction (now formally approved) Type 1 Diabetes (investigational
Mild instances could show up as a streak of red blood in the stool or on toilet paper after wiping
look for any changes in color or consistency
Superoxide anions are one of the strongest reactive oxygen species (ROS) and contribute to many health challenges
Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS)
Kengzi Jinsha Community, Pingshan District, Shenzhen, Guangdong 518118, China (CHN) Distributed by: Hikma Pharmaceuticals USA Inc